Pfizer director granted 1,543.845 phantom units
Taraporevala Cyrus reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Taraporevala Cyrus reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Cyrus Taraporevala received a compensation-related award of phantom stock units. On this date, he was granted 1,543.845 Phantom Stock Units linked to Pfizer common stock at a reference price of $24.29 per unit.
Each unit represents one phantom share of common stock and is part of deferred director compensation, including dividend equivalents. These units will be settled in cash or common stock, at the director’s election, after he retires from Pfizer’s Board. Following this award, his balance of phantom stock units stands at 36,941.287.
Positive
- None.
Negative
- None.
Insights
Routine deferred equity-style award, not an open-market trade.
This filing shows Cyrus Taraporevala, a director of Pfizer, receiving 1,543.845 Phantom Stock Units as deferred compensation. The units track common stock value at a reference of $24.29 per unit and settle in cash or stock after board retirement.
Because this is a grant classified as deferred director compensation with settlement tied to retirement, it is a standard governance and pay mechanism rather than a discretionary market purchase or sale. It does not provide a strong trading signal but confirms continued use of equity-linked incentives for directors.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Phantom Stock Units | 1,543.845 | $24.29 | $37K |
Footnotes (2)
- F1. Each unit represents one phantom share of common stock.
- F2. These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
AI-generated analysis. How Rhea-AI works. Not financial advice.